iXCells Biotechnologies USA, Inc. (“iXCells”), a leading provider of human cell-based solutions and custom iPSC services, today announced the delivery of over 500 characterized induced pluripotent stem cell (iPSC) lines as part of a multi-year collaboration with a global biotechnology company.